Shares of Macrocure Ltd (NASDAQ:MCUR) are down significantly today following last week’s impressive rally. Trading as low as $0.88 as recently as November 18th, the stock exploded for triple digit percentage gains on high volume over a period of the last six trading days.
This rally at least slowed down for the time being this afternoon as shares tumbled, thanks to shareholders taking some of their profits off the table. With no major news hitting over the holiday weekend, besides a change to the Board of Directors, where the company will be replacing Chairman David Ben-Ami with Tomer Kariv, this move is likely based more on fundamentals rather than anything else.
The stock is down 15.02% or $0.37 after the news, hitting $2.07 per share. About 1.85M shares traded hands or 14.91% up from the average. MCUR has declined 73.45% since April 27, 2015 and is downtrending. It has underperformed by 72.56% the S&P500.
Out of 5 analysts covering Macrocure (NASDAQ:MCUR), 0 rate it “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. $20 is the highest target while $1 is the lowest. The $7.50 average target is 262.32% above today’s ($2.07) stock price. Macrocure was the topic in 9 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Zacks upgraded the stock on September 7 to “Hold” rating. Oppenheimer maintained the shares of MCUR in a report on August 20 with “Perform” rating.
MacroCure Ltd. is a biotechnology company. The company has a market cap of $39.34 million. The Firm is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers (VLUs). It currently has negative earnings. The Company’s product candidate, CureXcell, is an advanced wound care (AWC) therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process.